Cell kinetics as a prognostic indicator in node-negative breast cancer.

Area of Science:

• Oncology
• Cell Biology
• Cancer Prognostics

Background:

• Prognostic markers are crucial for selecting node-negative breast cancer patients for adjuvant therapy.
• Cell kinetics, specifically the [3H]thymidine labeling index (LI), has shown potential as a prognostic indicator.

Purpose of the Study:

• To assess the consistent prognostic role of cell kinetics (LI) in node-negative breast cancer patients over time.
• To evaluate the correlation between LI values and disease recurrence, metastasis, and mortality.
• To determine if LI retains prognostic significance when considering tumor size and estrogen receptor status.

Main Methods:

• Retrospective analysis of 354 node-negative breast cancer patients treated with Halsted or modified radical mastectomy.
• Evaluation of cell kinetics using the [3H]thymidine labeling index (LI).
• Statistical analysis including multiple regression to assess prognostic significance.

Main Results:

• Disease recurrence and death risk were proportional to LI values.
• Tumors with high LI (>2.8%) showed a significantly higher 6-year probability of metastasis (41% vs. 25%) and death (19% vs. 5%).
• High LI tumors had a twofold increased risk of relapse within 2 years post-mastectomy.
• LI remained a significant prognostic factor for relapse-free and overall survival, independent of tumor size and estrogen receptor status.

Conclusions:

• Cell kinetics (LI) is a consistent and significant prognostic factor in node-negative breast cancer.
• LI can identify high-risk patients who may benefit from adjuvant chemotherapy.
• The prognostic value of LI is independent of menopausal status, tumor size, and estrogen receptor status.